Viola Davis says shingles came at a time when she was "running myself into the ground" while balancing motherhood and her busy career
The actress, 61, says she learned to prioritize her health in a better way and learned the "key to aging beautifully"
Davis now partners with GSK to encourage adults over 50 to discuss shingles prevention with their doctors
Shingles was never on Viola Davis' radar until she was left with "debilitating pain" one day. After dealing with the viral infection more than once, the EGOT winner, 61, is opening up to PEOPLE about her "unusual case" of shingles and how it completely changed her approach to aging.
"I was a new mom. I had just adopted my daughter. I was riding off of my Oscar nomination after The Help. So I was working, working, working, running myself into the ground," she recalls.

#viola #running #learned #egot

Hirata Runa, an 8-year-old trainee with the ******* anese idol program DIANNA Project, has died only days after what became her final public performance.
DIANNA Project announced on September 28 that the Nagoya trainee died from myocarditis ******* ociated with an influenza infection. A message later shared through Runa's social account said she died at around 4 a.m. on September 25.
Five days earlier, Runa had appeared at DIANNA Project's Regular Live Vol. 70 on September 20. She posted after the event to thank supporters and wrote that she had enjoyed the performance, a message that became her final public post.
The agency thanked fans and others who had supported Runa and said her wake and funeral were held privately with close relatives. It also asked the public and media to respect the family's privacy as they mourn.
Runa appeared at DIANNA Project's Regular Live Vol. 70 on September 20 as one of the project's Nagoya trainees. ******* anese outlet Nikkan Sports reported that the appearance became her final performance.

#became

Queen Mette-Marit of Norway pulled out of a major event due to another health setback
Mette-Marit is battling a respiratory infection following her lung transplant in June
Crown Princess Ingrid Alexandra stood in for her mother, joining the King at the official opening of the Norwegian government on Oct. 2
Crown Princess Ingrid Alexandra of Norway stepped in for her mother, Queen Mette-Marit, at a major royal event.
On Friday, Oct. 2, King Haakon attended the state opening of the 171st Storting —Norway's supreme unicameral legislature and national parliament — in Oslo. His wife was unable to join him due to a respiratory infection.

#queen #crown #alexandra #king

STERIS plc (STE), with a market capitalization of approximately $20.8 billion, is a global healthcare company focused on infection prevention and patient care. The Mentor, Ohio-based company provides consumable products, capital equipment, maintenance and repair services, sterilization solutions, laboratory testing, outsourced reprocessing, and operating room connectivity solutions.
Companies worth between $10 billion and $200 billion are generally classified as "large-cap stocks," and STERIS fits this description, with its market capitalization reflecting its substantial size and established position within the healthcare sector. STERIS stands out by combining a leading position in infection prevention with a broad range of healthcare and sterilization products and services. Its trusted brand, loyal customer base, strong financial position, and strategic acquisitions strengthen its competitive position while supporting continued expansion and innovation.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
Nvidia CEO Jensen Huang Just Dropped Huge News for This Cybersecurity Stock
How to Play GME Stock as GameStop CEO Ryan Cohen Buys $20.3 Million in Shares

#steris #position

A commonly used drug has been linked to a higher risk of death in a new study.
The antibiotic, cefepime, which is used to treat bacterial infections like pneumonia, UTIs and skin infections, is typically administered via injection by healthcare providers in a clinical setting.
Severe side effects may include confusion, decreased consciousness or seizures, especially in older patients and those with kidney problems, among many other common symptoms, according to Mayo Clinic.
Older Adults Taking 5 Or More Prescription Drugs Face Higher Risk Of Death, Study Finds
New research suggests the medication may be ****** ociated with a higher risk of all-cause mortality.

#risk

Army dentists say war games omit dental emergencies that could strain wartime casualty evacuation.
Broken equipment and limited supplies can hinder field dental training opportunities.
Forward dental teams can treat patients quickly and return them to duty.
A painful toothache or an oral infection might not sound like an injury that could sideline a soldier in combat, but US Army dental leaders warn that in a future conflict, such easily overlooked conditions could take troops out of the fight, consume scarce evacuation capacity, and further stress a strained medical system.
Most of the Army's major exercises don't include dental emergencies in their casualty scenarios, dentists said in a recent professional article, leaving commanders with an incomplete picture of the medical and triage or evacuation demands they could face in large-scale combat.

#evacuation #army #casualty #combat

KINSHASA, Congo (AP) — The Ebola outbreak in eastern Congo, the world's fastest-growing outbreak of the disease on record, has now spread to seven provinces in the African country, local authorities said. And it's showing no signs of slowing down.
According to the governor of the northwestern province of Sud-Ubangi, Jean-Rene Galekwa Vundawe, laboratory tests by Congo's national research institute found in a sample the Bundibugyo virus, the rare kind of Ebola that caused the current outbreak.
The statement, which was issued on Thursday and reported by local media outlets on Friday, said the sample was from the Bulu health district in Sud-Ubangi. It did not disclose other information about the source of the infection.
The development makes Sud-Ubangi the seventh province affected by the outbreak — and the first in western Congo — a worrisome spread west from what was previously concentrated in the country's east. A case was detected in Kinshasa in May in a person who had traveled from eastern Congo, but the Congolese capital was not classified as an affected province.
As of Wednesday, 6,942 cases and 3,349 deaths have been reported, according to the latest government figures.

#outbreak #local

Pamela Anderson has recalled being given "a death sentence" when she was diagnosed with hepatitis C in the late '90s.
The Baywatch actress gave a powerful speech about her diagnosis and recovery from the virus as she was honoured with amfAR's Award of Courage during the Venice Film Festival on Sunday night.
"It was a death sentence. That's what my doctor told me - that I probably had around 10 years to live," the 59-year-old told the audience, according to Variety. "I'm sure that coloured and corrupted my decisions. It was not fear of death, but fear of what might happen to my young children. It turned my life inside out."
A cure for the viral infection was found in 2011, and Anderson became "hep C free" in 2015 after paying "everything I had in my bank" to receive treatment.
"But my experience of shame and guilt was also an unconscious journey. It stays with me; it haunts me," she continued. "And just like the ******* ual abuse that I endured as a child, it felt like it was carved into my forehead: Damaged goods. And I presented myself as such."
The Last Showgirl star admitted that she has "finally come to terms" with her health news and is using that to fuel her career renaissance.

#death #like #pamela

Pamela Anderson received the Award of Courage from amfAR at the non-profit's Gala Venezia on Sept. 6
In her acceptance speech, the Rosebush Pruning actress opened up about her 2002 hepatitis C diagnosis
Calling the viral infection "a death sentence" at the time, Anderson said, "I'm not a victim, I'm a victor"
Pamela Anderson is looking back at a harrowing medical diagnosis.
The actress took the stage at the amfAR Gala Venezia 2026 on Sunday, Sept. 6 and gave a powerful speech reflecting on contracting hepatitis C in 2002. The amfAR event, held at Hilton Molino Stucky in Venice, Italy during the Venice Film Festival, honored Anderson, 59, with the non-profit's Award of Courage.

#award

On August 5, OraSure Technologies (NASDAQ:OSUR) reported second-quarter 2026 results that included its first GAAP net income in years, a headline number of $6.2 million versus a $19.7 million loss a year earlier. Revenue of $30.6 million beat the company's own guidance range and climbed 9.7% from the prior quarter. But look past the top line and the story splits in two, one part driven by real operating progress, the other by an accounting adjustment tied to a regulatory setback.
Some of this quarter's improvement came from actual operations. Gross margin expanded to 43.5% on a GAAP basis, up from 42.1% a year earlier, and non-GAAP gross margin rose to 44.2% from 43.2%. Diagnostics revenue grew 1% year over year to $19.4 million, helped by higher syphilis test sales and the addition of BioMedomics' Sickle SCAN product line. OraSure also picked up two regulatory wins during the quarter. In June 2026, the FDA cleared its Colli-Pee Dx urine collection kit for use with Roche's **** ually transmitted infection tests, letting patients collect samples at home instead of in a clinic.
The following month, the FDA granted Emergency Use Authorization for the second-generation OraQuick Ebola 2.0 Rapid Antigen Test, which can detect all four Ebola virus strains known to cause disease in humans. Cash used in operating activities improved to $23.8 million over the first six months of 2026, down from $30 million a year earlier, a sign the cash burn is easing. The company also kept buying back stock, repurchasing $22 million of shares, or 7.7 million shares, against its $40 million authorization, retiring more than 10% of shares outstanding.
The GAAP profit that headlines this quarter didn't come from the business getting more profitable. It came almost entirely from a $22.6 million reduction in a contingent consideration liability, an accounting entry triggered when OraSure updated its regulatory submission plan for the CT/NG test on its Sherlock platform. Strip that adjustment out and the underlying trend looks different. Non-GAAP operating loss widened to $14.7 million from $13.2 million a year earlier, and non-GAAP net loss came in at $13.8 million, roughly in line with last year's $14.2 million loss. The regulatory event behind that accounting gain is itself a setback.
In July, OraSure withdrew its InteliQuick CT/NG molecular self-test submission after receiving FDA feedback, meaning the product's path to market is now delayed while the company prepares a future resubmission. Total revenue for the quarter was still down 2% year over year, and core revenue, which excludes COVID-19 and Risk **** sment Testing, was flat. Six-month revenue fell 4% to $58.6 million. Sample Management Solutions revenue stayed flat year over year at $9.9 million, showing no growth driver of its own. Cash and equivalents fell to $161 million at quarter-end from $199.3 million at the end of 2025, pulled down by continued buybacks and cash used in operations.

#year #gaap #reven

Back when Pamela Anderson was diagnosed with hepatitis C in the '90s, her doctor said she had about 10 years to live. "The Last Showgirl" star opened up about her diagnosis Sept. 6, as she received an award at the amfAR Gala in Venice. "Back in the late '90s, when I was diagnosed with hepatitis C, there was no cure," Anderson said. "I'm sure that colored and corrupted my decisions. It was not fear of death but fear of what might happen to my young children. It turned my life inside out."
The "Baywatch" actress disclosed her diagnosis in 2002, and said she got hepatitis C by sharing a needle with ex-husband rock drummer Tommy Lee. Lee has denied this. Hepatitis C, a viral infection that primarily affects the liver, can exist quietly in the body and is easy to overlook. The infection is spread from blood-to-blood contact. Sharing needles or syringes is the most common cause of new infections, according to Dr. William Carey, a senior hepatologist at Cleveland Clinic in Ohio.

#hepatitis #diagnosis #infection #pamela

Gilead Sciences (NASDAQ: GILD) has no major concerns about its HIV franchise until the next decade. That hasn't kept the pharmaceutical company from preparing for the loss of exclusivity for its legacy HIV therapies. Gilead has spent heavily on its pipeline, and that's paying off.
The company has received three Food and Drug (FDA) approvals over the past four months, and not coincidentally, its shares are up more than 21% so far this year, nearly doubling the S&P 500 index's rise. The most recent approval was on Aug. 27 for Bixlenvo as a daily pill to treat virologically suppressed adults with HIV.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Prior to that, on June 24, Trodelvy received two new approvals to treat triple-negative breast cancer. On May 22, the FDA granted Hepcludex accelerated approval to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis.
Despite the stock's rise and all the good news on the pipeline front, Gilead may be underrated. There are three reasons why I feel that is the case.

#gilead #NVIDIA #three

Foster City, California-based Gilead Sciences, Inc. (GILD) discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States and internationally. The company has a market cap of $185.9 billion and provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo for the treatment of HIV-1 infection in patients, as well as other related drugs.
Companies with a market cap of $10 billion or more are typically referred to as "large-cap stocks." GILD fits perfectly into that category, with its market cap exceeding this threshold and reflecting its substantial size and influence in the general drug manufacturers industry.
Nvidia CEO Jensen Huang Says His $3.5 Billion MediaTek Deal Is 'Not Circular' Because 'They Do Their Own Business'
Strategy's Strategy Appears to Have Failed, and the Outlook of MSTR Stock Is Unfavorable
A Potential ******* eX Deal Could Meaningfully Accelerate Growth for Technip Stock

#gild #deal #Stock #sciences

Qiagen N.V. (NYSE:QGEN) announced on August 10 that the U.S. FDA cleared its QIAstat-Dx BCID GPF Plus AMR Panel, marking the company's first entry into the U.S. bloodstream infection testing market. Operating on the QIAstat-Dx platform, which boasts over 5,200 global placements, the automated panel detects 20 gram-positive bacterial and fungal targets, alongside 10 genetic antimicrobial resistance markers, in about one hour.
This regulatory milestone comes shortly after Qiagen N.V. (NYSE:QGEN) reported solid Q2 2026 financial results on August 5. Net sales reached $535 million (flat YoY at constant exchange rates), beating guidance for a 2% decline. Adjusted diluted EPS rose 3% YoY to $0.62, topping expectations. Performance across core growth pillars (+5% CER), including Sample Technologies (+9% CER) and QIAcuity digital PCR, helped offset a 7% drop in QIAstat-Dx respiratory testing sales. QGEN reaffirmed its full-year 2026 outlook for 1%–2% CER net sales growth and adjusted EPS of at least $2.43.
Additionally, Qiagen announced that Jonathan Pratt will take over as CEO effective September 1, succeeding Thierry Bernard. Joining at a pivotal time, Pratt will lead executive execution following an intensive portfolio evaluation and ongoing corporate efficiency programs.
This brings up a key question: Does the FDA clearance and steady execution under incoming leadership position Qiagen N.V. (NYSE:QGEN) for a valuation rerating, or will soft regional demand and product mix headwinds keep shares range-bound?
Bulls argue that Qiagen's high-margin, consumable-driven business model (comprising 90% of total Q2 sales) provides defensive recurring cash flow, generating $301 million in H1 operating cash flow. The new FDA approval expands QIAstat-Dx into its fourth major infectious disease area in the U.S., unlocking higher-margin hospital diagnostic channels. Furthermore, solid growth across core pillars like Sample Technologies and QIAcuity demonstrates fundamental demand. Strong internal cash generation also gives incoming CEO Jonathan Pratt ample balance sheet capacity to pursue disciplined capital deployment and portfolio innovation.

#qiagen

The next few years will test whether Pfizer Inc. (NYSE:PFE) can replace yesterday's blockbusters, and whether Gilead Sciences, Inc. (NASDAQ:GILD) can become more than an HIV company. Pfizer's (NYSE:PFE) newer medicines are gaining traction, but that growth has yet to accelerate the wider business. Gilead (NASDAQ:GILD) is expanding faster, although its performance remains concentrated in one therapeutic area. For investors, this is ultimately a choice between an unfinished turnaround and a stronger growth story still searching for greater breadth.
Pfizer's (NYSE:PFE) strongest result was the performance of its non-COVID portfolio. Revenue excluding Comirnaty and Paxlovid grew 5% operationally, while launched and acquired products generated $3.2 billion and increased 18% operationally. Growth also came from several franchises. Padcev revenue rose 23% operationally to $667 million, supported by increased market share in bladder cancer. The Vyndaqel family generated $1.76 billion, up 8% operationally, while Lorbrena grew 37% operationally. These products give Pfizer more than one avenue for rebuilding revenue as COVID-related demand declines.
Pfizer (NYSE:PFE) lowered its 2026 COVID-product forecast from approximately $5 billion to $4 billion after low infection levels weighed on Paxlovid utilization. Nevertheless, stronger-than-expected non-COVID sales allowed the company to raise the midpoint of its total revenue guidance by $500 million. Cost reductions provide additional support for the company. Pfizer (NYSE:PFE) expects approximately $6.7 billion in savings from its cost-realignment program through 2029. A separate manufacturing-optimization program is expected to generate another $3 billion, bringing anticipated savings across the two programs to approximately $9.7 billion. This leaner cost base could help Pfizer (NYSE:PFE) preserve margins and continue investing in areas such as oncology and obesity.
Gilead (NASDAQ:GILD), however, is currently delivering much stronger underlying growth. Product sales excluding Veklury increased 10% to $7.6 billion, and HIV sales rose 12% to $5.7 billion, with Biktarvy revenue increasing 7% to $3.8 billion and Descovy sales climbing 48% to $967 million. Yeztugo, Gilead's (NASDAQ:GILD) twice-yearly injectable HIV-prevention medicine, contributed $232 million as its launch gained momentum. The product adds a potentially important growth driver to an already dominant HIV portfolio.
Growth, however, was not confined to HIV alone, as liver-disease sales increased 10% to $877 million, while Livdelzi revenue more than doubled from $78 million to $167 million. Trodelvy sales rose 26% to $457 million, providing further evidence that Gilead (NASDAQ:GILD) is building a meaningful oncology franchise. Management subsequently raised its 2026 product-sales outlook to $30.1–$30.4 billion and increased guidance for product sales excluding Veklury to $29.8–$30.1 billion.

#NYSE #million #gild

Kylie Jenner honored her late hairstylist and friend, Jesus Guerrero, on his birthday over one year after his death at age 34 in February 2025
"Until we meet again, my angel," the mogul wrote in a tribute shared to Instagram
Guerrero, who also worked with Jennifer Lopez, died from pneumonia and a fungal infection
Kylie Jenner is celebrating the birthday of her late hairstylist and friend, Jesus Guerrero.
In an Instagram Stories post on Sunday, Aug. 23, the mogul, 29, honored Guerrero by resharing her tribute post she originally shared after his death in February 2025.

#jesus #Instagram

NEW DELHI: India made one change to their playing XI for the second Test against Sri Lanka in Colombo on Sunday, with Kuldeep Yadav missing out after failing to fully recover from a viral infection and Saransh Jain making his Test debut.

India captain Shubman Gill won the toss and elected to bat first, with the hosts also handing Test debuts to Kamil Mishara and Pasindu Sooriyabandara.

India entered the second Test with an unassailable 1-0 lead after their 165-run victory in the series opener at Galle. However, Kuldeep's absence meant India had to alter their combination, with Jain coming into the XI as the spin-bowling allrounder.

The Board of Control for Cricket in India (BCCI) confirmed that Kuldeep remains unavailable for selection but could still be used in a specific situation.

"Mr Kuldeep Yadav has not fully recovered from his viral illness. He was unavailable for selection in the Playing XI for the second Test against Sri Lanka. However, he can take the field as a concussion substitute, if required," the BCCI said.
Gill also addressed Kuldeep's absence after winning the toss, confirming that an infection had ruled out the left-arm wristspinner.

"[Playing XI] Kuldeep, unfortunately, had some infections, so he misses out, and Saransh makes his debut for India," Gill said.

With Kuldeep unavailable, Jain received his first opportunity at Test level. The 33-year-old was presented his India cap by Ravindra Jadeja during the team's huddle before the start of play.

Jain becomes the first India player to make his international debut after turning 33 since Robin Singh in 1998.
Gill opted to bat after ******* sing the Colombo surface and felt it offered better batting conditions than the pitch in Galle.

"Batting first, yes. [On the pitch] It looks like a much harder, much better surface compared to Galle. Galle was also a very good wicket, but I think as the game went on, it got a little bit slower and the ball started to turn. We're expecting the same, but I think for the first two or three days, I think it'll be a really good wicket to bat on," Gill said.

Reflecting on India's dominant win in the first Test, Gill rated the team's performance highly but admitted there was still room for improvement.

"[How he would rate the Galle win] I would say probably a nine, because there's always room for improvement, and I think we played a pretty good match, a decent match. And obviously there were some areas where we could have got a little bit better, but, you know, this is Test cricket. It's very, very difficult to be able to have a near-perfect game because you're playing for five days, and to play that dominant and consistent cricket, especially in Test, is hard. But I think overall we had a pretty good match," Gill said.
India Playing XI: Yashasvi Jaiswal, KL Rahul, Devdutt Padikkal, Shubman Gill(c), Rishabh Pant(w), Ravindra Jadeja, Dhruv Jurel, Saransh Jain, Manav Suthar, Mohammed Siraj, Prasidh Krishna
Sri Lanka P

Liverpool targets Bradley Barcola (23) and Ibrahim Mbaye (18) are not expected to make PSG's matchday squad for their Ligue 1 opener against Rennes, according to Onze Mondial. The pair also sat out last week's Trophée des Champions against RC Lens. Both Barcola and Mbaye are expected to leave Les Parisiens in the final days of this summer transfer window. The France international is Liverpool's priority target to reinforce up front with talks reportedly making slow progress with the back-to-back UEFA Champions League winners.
Both Barcola and Mbaye took part in PSG's training session on Saturday, but they won't make Sunday's trip to Brittany. PSG were initially poised to host Rennes at Parc des Princes, but the ground's pitch has been hit with a fungal infection. The game will therefore be played at Roazhon Park. However, it remains to be seen whether PSG will host the return leg as Ligue 1.
GFFN | Bastien Cheval

#barcola #rennes #host #Liverpool

Fight fans tuned in to LFA 239 on Friday night (Aug. 22, 2026) in hopes of some memorable MMA action, but instead they ended up witnessing one of the worst cases of staph infection to ever enter the cage.
Friday's LFA 239 event in Ventura, Calif., was headlined by a featherweight clash between Chris Mecate and Manuel Exposito. The fight itself was an entertaining back-and-forth that saw Mecate walk away with the unanimous decision win, but that's not what fans will remember the most. It will be the apparent staph infection that made Mecate's back look like it was about to pop.
While fight fans have seen some gnarly staph infections over the years it's usually not big enough to make a noticeable difference. That was not the case on Friday as Mecate's alleged staph infection took up a whole portion of his back. Making matters worse is that Exposito kept making contact with it. It's hard not to throughout 15 minutes of fighting, but still a gross scene to say the least.
Check it out below:
Of course, fight fans were quick to notice the main event gross fest and quickly took to social media to discuss. Not only were they disgusted by the actual ailment, but many called out the California State Athletic Commission for allowing Mecate to compete in the first place.

#fans #mecate #exposito #Event

(NEXSTAR) – Don't be surprised if you start hearing some more coughing in the next few weeks. COVID-19 is once again on the rise in nearly every corner of the U.S.
According to modeling done by the Centers for Disease Control and Prevention, "COVID-19 infections are growing or likely growing in 50 states." No states are seeing cases decline, as of mid-August.
Despite the trend, the CDC says severe cases are still pretty rare. Emergency department visits related to COVID are "very low."
Epidemic trend tracking by the CDC shows COVID 'growing' or 'likely growing' in every state. No estimate was given for Iowa. (Map: CDC)
Wastewater data can give us a closer look at where the virus may be circulating most. Testing the sewage can pick up the presence of COVID-19 in a community and "can pick up signs of infection even from people who feel perfectly healthy," the CDC says.

#growing #every #states #don 't

Becton, **** inson and Company (BDX) develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products. Valued at $50.5 billion by market cap, the company offers solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, and promote infection prevention.
Shares of this global medical technology giant have underperformed the broader market over the past year. BDX has gained 19.6% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 20.4%. However, in 2026, BDX stock is up 20.2%, surpassing the SPX's 13.7% rise on a YTD basis.
CoreWeave vs Nebius: Both Companies Reported Strong Earnings, But Here's the Stock You Should Buy
A $210 Billion Reason to Buy AMD Stock Here
As Oracle Deepens Its Partnership with AWS, Here's How You Should Play ORCL Stock

#medical #billion

In the final Bundesliga match of the 2022/23 season at home to 1. FFC Turbine Potsdam (Sunday 28 May, 14:00 CEST), FC Bayern Women can secure the championship with a win. Before kick-off, four players who are leaving the club at the end of the season will say their goodbyes: Laura Benkarth, Ivana Rudelić, Saki ***** agai and Emelyne Laurent. FC Bayern says thanks and Servus!
72 appearances, 55 wins and 43 clean sheets! Laura Benkarth kept the ball out of the FC Bayern net for a long time. As the number one during the 2020/21 season, the Freiburg native played a key role in the ***** le win, conceding just one goal - a penalty - in the entire first half of the season. After five years in the FCB shirt, the cheerful 30-year-old is leaving the club at the end of this season. On the pitch, Laura had command of her defence and passed on her many years of experience to the young goalkeepers at Bayern in training and on matchdays.
Many thanks for your service and your infection happiness over the last five years, Laura! We wish you only the best for the future!
After returning to the Bavarian capital at the start of 2021, Ivana Rudelić is now leaving Bayern. The striker first plied her trade for the Reds from 2008 to 2014, before rejoining seven years later. During her first stint with the club, the Croatian international lifted the DFB Cup in 2012, when she scored the goal to make it 2-0 in the final. She also celebrated the championship with the team in 2021.
Dear Ivana, many thanks for your commitment in the Bayern shirt. FCB wishes you all the very best!

#club #first

NEW YORK (AP) — Bedbugs are sometimes called the vampires of the insect world — hiding during the day and coming out at night to feast on human blood. Generations of children have been told: "Sleep tight. Don't let the bedbugs bite."
Well, bad news: Bedbug infestations are increasing. This is the time of year when they tend to be at their worst. And some scientists think the reviled pests might be capable of spreading an antibiotic-resistant infection called MRSA.
For centuries, the bugs have horrified homeowners and occasionally panicked the public. That happened in New York City in 2018, when at least a half dozen city buses were taken out of service after reports of bedbugs crawling on seats. It happened again in Paris in 2023, when reports of bedbugs at a movie theater, on trains and on buses popped up in the lead-up to the 2024 Olympics.
"They certainly are out there," said Christopher Hayes, a North Carolina State University ******* istant professor who has been bitten by bedbugs more than 50 times in the course of research. "And if you're unaware, if you're not on top of your game, it's easy to bring them into your home."
Bedbugs are reddish-brown bloodsuckers about the size of an apple seed. Some researchers estimate they date back to the time of the dinosaurs, but they are best known for their unfortunate ability to live with — and prey on — humans.

#called #buses #reports

Qiagen (NYSE:QGEN) walked into its second quarter of 2026 bracing investors for a roughly 2% sales decline. Instead, net sales came in flat at $535 million on August 6, and adjusted diluted EPS hit $0.62, both ahead of the company's own outlook. For a diagnostics and life sciences supplier still working through the loss of discontinued product lines, beating a cautious bar is one thing. What happens next, as management leans on a stack of new launches to carry the back half of the year, is the more interesting question.
The company's so-called growth pillars, the businesses management is counting on to outpace the broader market, expanded 5% at constant exchange rates in the quarter. Sample Technologies led with 9% CER growth, driven by automated consumables and higher instrument sales. QIAcuity, the digital PCR platform, posted double-digit consumables growth even as weaker OEM demand offset some of that strength. QuantiFERON, the tuberculosis test that had flagged a sharp drop in US immigration testing demand back in the first quarter, still managed to return to growth as demand across other testing groups more than made up the difference.
Behind those numbers sits a wave of product activity. QIAsymphony Connect launched commercially, QIAsprint Connect placements are drawing what management called strong pharma customer acceptance, and two new bloodstream infection panels for QIAstat launched in Europe, detecting 33 pathogens and 28 resistance markers in about an hour, with US FDA approval targeted by year-end. Parse, the single-cell ****** ysis business, is running ahead of its roughly $40 million 2026 sales target and was selected for a NASA-supported research program aboard the International ****** e Station. Qiagen also completed a $500 million share repurchase in January and raised its annual dividend 40% to $0.35 per share.
The flat top line masks uneven performance underneath. Diagnostic solutions overall declined 2% at constant currency, and PCR and nucleic acid amplification sales fell 8%, with QIAstat-Dx down 7% as a tough prior-year comparison in respiratory testing outweighed gains in gastrointestinal and meningitis panels. Profitability also gave ground. Adjusted operating income fell 2% to $157 million, with the margin slipping to 29.4% from 29.9% a year earlier, and adjusted gross margin declined to 66.2% from 66.7% on product mix shifts.
Regionally, EMEA sales fell 2% CER as declines in Germany, France, and Italy outweighed gains elsewhere, and Asia Pacific sales fell 2% CER as China dropped in the low teens, even though it improved sequentially. Inventory days outstanding also climbed to 153 from 149, tied to stockpiling ahead of new launches. The company is now guiding to a jump from roughly negative 1% CER sales growth in the first half to 3% to 4% in the second half, a swing that leans heavily on new products, easier comparisons and the fading drag from discontinued lines all landing on schedule.

#Growth #adjusted #ro

An outbreak of cyclosporiasis, a parasitic infection known for causing explosive diarrhea that has been linked to recalled iceberg lettuce, has expanded to two additional states since early August, according to the Centers for Disease Control and Prevention (CDC).
An unprecedented wave of infections has hit the United States since May, resulting in thousands of illnesses and two deaths. The CDC, which lags significantly behind states in reporting infections, pinpointed 13,895 laboratory-confirmed cases across 47 states between May 1 and its latest update on Aug. 10. At least 10,455 additional cases have not yet been confirmed by laboratories, the CDC said.
Is lettuce safe to eat now? What to know amid cyclospora outbreak
Ohio and Michigan have led the charge in reporting cyclosporiasis incidents, with Michigan's health department stating on Aug. 13 that it had 13,909 cases, including the first two deaths identified in the nationwide outbreak.
Cyclosporiasis, an illness caused by the parasite Cyclospora cayetanensis, results in unpleasant gastrointestinal symptoms, often ****** ociated with food poisoning, such as diarrhea, nausea and vomiting. It is usually contracted through contaminated food or water, and it is not generally known to be deadly; however, it can cause more serious complications in people with compromised immune systems or other underlying health issues.

#lettuce

(NewsNation) — A former director of the U.S. Centers for Disease Control and Prevention faults the federal government for recommending that pregnant women take mRNA vaccines during the COVID pandemic.
Dr. Robert Redfield, who headed the CDC during the pandemic, joined "Katie Pavlich Tonight" to comment on revived discussion about whether the vaccine can cause miscarriages in women early in their pregnancy.
He said he hasn't seen data establishing a link but said it made no sense to recommend the vaccine to expectant mothers.
Breaking down Republican accusations against Anthony Fauci
"I never thought we should vaccinate pregnant women. I was not in favor of that policy recommendation because the COVID vaccine did not prevent infection," Redfield said Tuesday.

#vaccine #pandemic

Bella Ramsey's friendship with Pedro Pascal on "The Last of Us" generated plenty of buzz among fans, but the 22-year-old actor can't seem to understand the fuss about it.
In a recent interview, Ramsey, who identifies as non-binary and uses they/them **** ouns, hinted that their relationship has changed and admitted it was "sort of weird to talk about it."
They also discussed their **** uality, explaining that they're not "100% straight," and said they aren't particularly bothered by being misgendered as long as people remain respectful.
Bella Ramsey suggested they and Pedro Pascal are no longer as close as they once appeared to be following the buzz they generated on "The Last of Us." In a recent interview with The Guardian, the Emmy-nominated actor revealed that the pair are now "loosely in touch."
Ramsey and Pascal's relationship became a major talking point after the first installment of the hit series, in which his character, Joel, was tasked with escorting their character, Ellie, across the United States following the collapse of society caused by a mass fungal infection that turns its hosts into zombie-like creatures.

#ramsey #bella #buzz

Health officials in Louisiana are urging beachgoers to take precautions during a summertime surge in infections from a flesh-eating bacteria found in coastal waters.
Louisiana has confirmed nine cases of Vibrio vulnificus infections this year, the state's health department said last week in a news release. All were hospitalized, and five died. During the same period over the previous decade, Louisiana reported an average of seven cases and one death.
"Seek medical care immediately if a wound exposed to brackish or salt water becomes red, swollen, painful, warm or discolored," officials said in the release. "Tell the health care provider about the water exposure."
Vibrio bacteria thrive in seawater and in the brackish mix of fresh and saltwater found in estuaries and lagoons. Most infections are reported from May to October, and most happen in states along the Gulf Coast. Doctors say the Gulf is an ideal environment with the right amounts of salt and heat to let this organism proliferate.
The mostly deadly type is Vibrio vulnificus, according to the Centers for Disease Control and Prevention. As many as one in five of those infections are fatal, a much higher rate than other types of Vibrio bacteria.

#vibrio #bacteria #found

Five people have died in Louisiana from flesh-eating bacteria infections so far in 2026, state health officials said on August 6.
A total of nine cases of Vibrio vulnificus bacteria have been reported in 2026 in the state, the Louisiana Department of Health reported. All nine patients had underlying health conditions and were hospitalized after wounds had been exposed to seawater, officials said.
Vibrio vulnificus is often called "flesh-eating bacteria" because an infection can eat away at flesh around a wound. Infections can occur when an open wound is exposed to salt water or brackish water, where rivers meet the ocean and fresh water mixes with salt water, according to the Centers for Disease Control and Prevention.
Louisiana health officials warned residents to take precautions to prevent infections because the bacterium's presence increases as coastal waters get warmer. Cases in Louisiana are higher than in past years, officials said. During the same period over the previous 10 years, Louisiana reported an annual average of seven cases and one death.
Florida recently reported its second Vibrio vulnificus infection death of the year.

#vibrio #water #flesh

Florida health officials confirmed on Thursday that a second person has died in the state from the flesh-eating bacterium Vibrio vulnificus. The second death was reported in Marion County, and the first was reported in Palm Beach County. It marks the second death in the U.S. this year.
There have been 14 other cases confirmed across Florida, according to the state's health department. Elsewhere, there have been a total of six confirmed cases in Alabama, while Connecticut detected a case in February, according to state public health departments.
They come as Stony Brook University announced new research in April, finding that some bays and waterways off the coast of Long Island, N.Y., have developed the right conditions for Vibrio vulnificus to thrive.
Vibrio vulnificus cases are considered rare, with between 100 and 200 infections reported in the U.S. each year, according to the Cleveland Clinic. However, many people with an infection can become seriously ill, requiring intensive care or limb amputation. "About 1 in 5 people with this infection die, sometimes within a day or two of becoming ill," according to the Centers for Disease Control and Prevention.
Infections caused by other Vibrio species are much more common, with about 80,000 cases of vibriosis per year.

#vibrio #cases #Florida